Tumor-associated antigen presented by dendritic cell major histocompatibility complex molecule

Tumor-associated antigens are proteins or peptides derived from cancer cells that can be recognized as foreign by the immune system. Dendritic cells, which are professional antigen-presenting cells, internalize these antigens through specific receptors. The internalized antigens are processed into short peptides and loaded onto major histocompatibility complex (MHC) molecules—either class I or class II—on the surface of dendritic cells. This process is essential for activating both helper CD4+ T-cells (via MHC II) and cytotoxic CD8+ T-cells (via MHC I), thereby initiating an anti-tumor immune response[1][2]. In cancer immunotherapy, strategies such as cancer vaccines aim to enhance this process so that more effective anti-tumor immunity is generated. However, this entry is not a single molecular target but rather describes a functional complex/process involving multiple components: the tumor-associated antigen itself, the dendritic cell's processing machinery, and its display via MHC molecules. Therefore, it does not correspond to a unique protein or receptor but rather to an immunological event critical in cancer therapy development[1][2]. Notably, impaired function in this pathway—such as defective cross-presentation due to lipid accumulation in DCs within tumors—can limit effective anti-tumor responses[2]. This entry should be flagged as "is_incorrect" because it refers broadly to an immunological mechanism rather than a discrete molecular entity suitable for structured drug-target databases.

Other names

Tumor antigen-MHC complex on dendritic cellTAA presented by DC MHCDendritic cell-presented tumor antigen

Induction of cytotoxic T-cell responses via presentation of tumor antigens on MHC molecules to activate adaptive immunity[1][2].